AMEX:PTN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Palatin Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PTN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.6%

PTN

-3.0%

US Biotechs

-1.3%

US Market


1 Year Return

-48.1%

PTN

33.9%

US Biotechs

18.5%

US Market

Return vs Industry: PTN underperformed the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: PTN underperformed the US Market which returned 18.5% over the past year.


Shareholder returns

PTNIndustryMarket
7 Day-6.6%-3.0%-1.3%
30 Day-21.7%1.8%5.3%
90 Day-28.4%-3.7%7.5%
1 Year-48.1%-48.1%36.2%33.9%21.3%18.5%
3 Year-43.5%-43.5%19.1%13.1%42.4%32.9%
5 Year-46.8%-46.8%15.2%7.0%84.2%63.5%

Price Volatility Vs. Market

How volatile is Palatin Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Palatin Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PTN ($0.42) is trading below our estimate of fair value ($14.74)

Significantly Below Fair Value: PTN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PTN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PTN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTN is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Palatin Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

23.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTN's revenue (44% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: PTN's revenue (44% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Palatin Technologies performed over the past 5 years?

53.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTN is currently unprofitable.

Growing Profit Margin: PTN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTN is unprofitable, but has reduced losses over the past 5 years at a rate of 53.6% per year.

Accelerating Growth: Unable to compare PTN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: PTN has a negative Return on Equity (-27.97%), as it is currently unprofitable.


Next Steps

Financial Health

How is Palatin Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: PTN's short term assets ($83.6M) exceed its short term liabilities ($3.9M).

Long Term Liabilities: PTN's short term assets ($83.6M) exceed its long term liabilities ($953.4K).


Debt to Equity History and Analysis

Debt Level: PTN is debt free.

Reducing Debt: PTN has no debt compared to 5 years ago when its debt to equity ratio was 80.7%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable PTN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: PTN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 38% per year.


Next Steps

Dividend

What is Palatin Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

12.2yrs

Average board tenure


CEO

Carl Spana (58 yo)

20.33yrs

Tenure

US$2,292,617

Compensation

Dr. Carl Spana, Ph.D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief ...


CEO Compensation Analysis

Compensation vs Market: Carl's total compensation ($USD2.29M) is above average for companies of similar size in the US market ($USD589.00K).

Compensation vs Earnings: Carl's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
John K. Prendergast
Co-Founder & Independent Non-Executive Chairman20.33yrsUS$212.30k0.17%
$ 166.1k
Carl Spana
Co-Founder20.33yrsUS$2.29m0.38%
$ 371.7k
Arlene Morris
Independent Director5.33yrsUS$138.45k0.080%
$ 77.2k
Robert deVeer
Independent Director21.92yrsUS$150.95k0.28%
$ 270.8k
Alan Dunton
Independent Director9.33yrsUS$150.95k0.089%
$ 86.0k
Anthony Manning
Independent Director3.08yrsUS$133.45k0.038%
$ 36.6k
Raymond Rosen
Member of Female Sexual Dysfunction Expert Panelno datano datano data
Michael Perelman
Member of Female Sexual Dysfunction Expert Panelno datano datano data
J. Hull
Independent Director15.08yrsUS$142.20k0.084%
$ 81.5k
Angela Rossetti
Independent Director7.33yrsUS$138.45k0.081%
$ 78.5k
Anita Clayton
Member of Female Sexual Dysfunction Expert Panelno datano datano data
Stanley Althof
Member of Female Sexual Dysfunction Expert Panelno datano datano data

12.2yrs

Average Tenure

66.5yo

Average Age

Experienced Board: PTN's board of directors are seasoned and experienced ( 12.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PTN insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Palatin Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Palatin Technologies, Inc.
  • Ticker: PTN
  • Exchange: AMEX
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$96.723m
  • Shares outstanding: 229.86m
  • Website: https://www.palatin.com

Number of Employees


Location

  • Palatin Technologies, Inc.
  • Cedar Brook Corporate Center
  • 4B Cedar Brook Drive
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTNAMEX (NYSE MKT LLC)YesCommon StockUSUSDOct 1993
PTNADB (Deutsche Boerse AG)YesCommon StockDEEUROct 1993
0KF3LSE (London Stock Exchange)YesCommon StockGBUSDOct 1993

Biography

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 23:54
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.